Empowering ADC Development with High-Quality Payload Solutions
In the dynamic and fast-evolving field of Antibody-Drug Conjugates (ADCs), the selection of High-Quality payloads is critical to balancing efficacy and safety. ADCs have emerged as one of the most rapidly expanding classes of anticancer therapeutics, with an increasing number of FDA-approved therapies and novel targets entering clinical trials. Targets such as HER2, EGFR, Trop2, CLDN18.2, and Nectin-4 have become cornerstones of ADC development, enabling the selective delivery of potent payloads to cancer cells while minimizing off-target toxicity. The advent of combination therapies and bispecific ADCs has further expanded the therapeutic potential of ADCs, offering solutions to challenges like tumor heterogeneity and drug resistance.
ChemExpress offers comprehensive end-to-end ADC Contract Development and Manufacturing Organization (CDMO) services. We specialize in Antibody, ADC payload-linker, ADC bioconjugation, ADC drug substance and ADC drug product, providing full support from R&D to commercialization.
We have a substantial inventory of over 80 payloads and 400 linkers, in addition to extensive expertise in linker compound synthesis, with over 1,000 successful syntheses. So far, we have 12 ADC-related intermediates and payloads with DMFs.
Key Products:
To strengthen our global capabilities and better serve the growing demand for ADC development, we established Chongqing Haoyuan Biopharmaceutical Co., Ltd., a subsidiary of ChemExpress. This new entity provides one-stop CDMO services for antibodies, payload linkers, bioconjugates, ADC drug substance and ADC drug products, offering end-to-end solutions to biotech and pharma companies from R&D to commercialization.
Click the link to download the ADC One-stop CDMO Services Brochure.
https://www.chemexpress.com/information-sheet.html?resources=brochure